We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multiplexed POC Testing IVD Solution Performs Molecular and Immunoassays from Various Body Fluids on Single Platform

By LabMedica International staff writers
Posted on 10 Jan 2024

A hybrid in vitro diagnostics (IVD) solution for multiplexed point-of-care testing (xPOCT) can perform both molecular and immunoassays from several body fluids on a single platform. More...

The hybrid and scalable technology aims to deliver lab-comparable test results in a single patient encounter, significantly reducing the diagnostic timeline.

Picodya’s B-Matrix diagnostic system is the world’s first POC hybrid solution that can run IVD tests, both immunoassays and molecular assays on the same device at lab-comparable quality, on multiple patient samples, simultaneously within minutes. The B-Matrix is designed to minimize turnaround time, and deliver better outcomes while lowering costs. The B-Matrix is powered by Picodya’s proprietary PicoFluidic technology which enables the system to operate at high capacity testing for a panel of markers simultaneously, using just pico volumes of reagents and controls. This allows for ultra-fast results within as quickly as 15 minutes and at a fraction of the cost for comparable tests. Additionally, the technology is scalable, making it suitable for all settings and throughputs.

The B-Matrix utilizes a unique Diagnostic Pack (DP) cartridge, the only PicoFluidic chip in the world that is capable of running hundreds of patient samples for a panel of syndromic tests using the same chip. The efficient use of minute reagent volumes by Picodya’s technology translates into substantial cost savings. Additionally, the system uses single-use Assay Packs (APs) pre-loaded with necessary reagents and a membrane slide for reactions to occur. Multiple APs, each containing a different patient sample, can be processed simultaneously for a chosen range of tests. The B-Matrix product suite is designed to meet the needs of healthcare providers in various environments, with platforms of varying sizes and throughputs. All B-Matrix platforms are built on the same core technology, ensuring compatibility with the same consumables and facilitating the introduction of new test assays.

Picodya’s B-Matrix has demonstrated its versatility through a feasibility study, confirming its ability to perform a wide array of immunoassays and molecular tests, including COVID-19, influenza, HBV, EBV, prostate cancer, and cardiologic markers. The system is being integrated into research facilities worldwide, to optimize diagnostic timelines and reduce costs. Picodya is advancing through its regulatory pathway, with post-approval plans to deploy the system across diverse healthcare settings and large-scale venues. The technology has already been implemented in NIH laboratories for global serologic surveillance, aiding in the real-time monitoring of human immune status and the detection of viral outbreaks.

"With our knowledge of the devastating impact of COVID-19 on global health and following years of research collaboration with the NIH for crisis preparedness, we are proud to proceed with the next phase of this important partnership," said Tzvika Barkai, Founder and Chief Executive Officer at Picodya. "We remain dedicated to enabling timely, precise, and comprehensive disease diagnosis capabilities to optimize potential outcomes. We plan to introduce the B-Matrix solution to additional research labs across the US, followed by the broader clinical market."

Related Links:
Picodya


New
Gold Member
Thyroid-Stimulating Hormone Test
ULTRA-TSH
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Mumps Test
ReQuest MUMPS IgM Assay
New
PBC Assay
Primary Biliary Cholangitis Assays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Results of AI-based 3D virtual H&E staining and quantitative analysis of pathological tissue (Photo courtesy of Nature Communications, DOI:10.1038/s41467-025-59820-0)

Virtual Staining Technology Paves Way for Non-Invasive Pathological Diagnosis

For more than 200 years, traditional pathology has depended on the technique of examining cancer tissues under a microscope, a method that provides only limited, specific cross-sections of the 3D structure... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.